Margarita Guenova

National Specialized Hospital for Active Treatment of Haematological Diseases -Sofia, Bulgaria

Professor Margarita Guenova, MD, Ph.D., runs the hematopathology and immunology diagnostics as a head of the laboratory and Professor of Hematology at the National Hematology Hospital, Sofia, Bulgaria. She specializes in the field of blood and lymphoid malignancies. Her scientific interests include the elucidation of critical mechanisms of leukemia pathogenesis and progression, investigation of clinically relevant biomarkers and potential therapeutic targets in leukemias and lymphomas, minimal residual disease and implementation of a multifaceted approach in diagnostics. Margarita Guenova has authored and co-authored many abstracts, articles in peer-reviewed journals and book chapters. She serves on editorial boards and executive boards and committees of medical societies such as the Bulgarian Joint Cancer Network, Bulgarian Society of Hematology, European Hematology Association, etc.

Margarita Guenova

4books edited

5chapters authored

Latest work with IntechOpen by Margarita Guenova

Medical professionals and researchers in the field of leukemias are faced with the need to continuously update their knowledge in a wide range of areas, ranging from fundamental molecular processes and mechanisms to a thorough understanding of clinical features and modern approaches to achieve maximum therapeutic results. This book does not have the ambition to present comprehensively the problems of leukemias, but it is an attempt to acquaint the audience of specialists involved in clinical management and experimental research with some modern advances and concepts in the three main directions: biology, clinical presentation and treatment. The biological aspects of the origin, development and therapy resistance of leukemias are within the scope of the first section. Comprehensive and concise information on the clinical assessment and treatment of leukemia patients is provided, as well as on some specific interdisciplinary clinical scenarios such as leukemic retinopathy, in the second section. Finally, challenges, current standards and recent advances in the therapy of acute leukemias comprise the third section of the book.

Go to the book